Rubraca and Skin disorder - a phase IV clinical study of FDA data

Summary:

Skin disorder is reported as a side effect among people who take Rubraca (rucaparib camsylate), especially for people who are female, 60+ old, have been taking the drug for < 1 month also take Emla, and have Ovarian cancer.

The phase IV clinical study analyzes which people have Skin disorder when taking Rubraca. It is created by eHealthMe based on reports of 10,770 people who have side effects when taking Rubraca from the FDA, and is updated regularly.

What is Rubraca?

Rubraca has active ingredients of rucaparib camsylate. eHealthMe is studying from 10,770 Rubraca users. Check the latest studies of Rubraca.

What is Skin disorder?

Skin disorder (skin disease) is found to be associated with 1,546 drugs and 1,450 conditions by eHealthMe. Check the latest studies of Skin disorder.

On Jul, 16, 2026

10,770 people reported to have side effects when taking Rubraca.
Among them, 20 people (0.19%) have Skin disorder.

Among these 20 people:

How long have people been on Rubraca when they have Skin disorder? *

What is the gender of people who have Skin disorder when taking Rubraca? *

female: 100 %
male: 0.0 %

What is the age of people who have Skin disorder when taking Rubraca? *

What are other drugs people take besides Rubraca? *

What are other side effects people have besides Skin disorder? *

Fatigue (feeling of tiredness): 12 people, 60.00%
Nausea (feeling of having an urge to vomit): 9 people, 45.00%
Itching: 8 people, 40.00%
Weakness: 5 people, 25.00%
Abdominal Discomfort: 4 people, 20.00%
Malignant Neoplasm Progression (cancer tumour came back): 4 people, 20.00%
Drowsiness: 3 people, 15.00%
Paraesthesia (sensation of tingling, tickling, prickling, pricking, or burning of a person's skin with no apparent long-term physical effect): 3 people, 15.00%
Constipation: 3 people, 15.00%
Dyspnea (difficult or laboured breathing): 3 people, 15.00%

What are the existing conditions these people have? *

Ovarian Cancer (cancer of ovary): 16 people, 80.00%
Endometrial Cancer: 3 people, 15.00%
Ovarian Cancer Recurrent (reoccurrence of ovary cancer): 1 person, 5.00%
Malignant Peritoneal Neoplasm (cancer tumour of peritoneum): 1 person, 5.00%
Fallopian Tube Cancer (cancer of fallopian tube): 1 person, 5.00%
Breast Cancer Female: 1 person, 5.00%

* Approximation only. Some reports may have incomplete information.

Do you take Rubraca and have Skin disorder?

- Check whether Skin disorder is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Rubraca:

Rubraca (10,770 reports)

Skin disorder treatments and more:

Skin disorder (41,532 reports)

Browse all side effects of Rubraca:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Skin disorder:

Skin disorder (1,546 drugs)

Browse all the conditions that are associated with Skin disorder:

Skin disorder (1,450 conditions)

Related publications that referenced our studies

Moftah NH, Kamel AM, Attia HM, El-Baz MZ, El–Moty HM, "Skin diseases in patients with primary psychiatric conditions: a hospital based study", Journal of epidemiology and global health, 2013 Sep .
Moftah NH, Kamel AM, Attia HM, El-Baz MZ, El–Moty HM, "Skin diseases in patients with primary psychiatric conditions: a hospital based study", Journal of epidemiology and global health, 2013 Sep .

How the study uses the data?

The study uses data from the FDA. It is based on rucaparib camsylate (the active ingredients of Rubraca) and Rubraca (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.